{"nctId":"NCT01457352","briefTitle":"Efficacy and Safety of SPARC0921 in Subjects With Spasticity","startDateStruct":{"date":"2012-11-14","type":"ACTUAL"},"conditions":["Spasticity"],"count":392,"armGroups":[{"label":"SPARC0921","type":"EXPERIMENTAL","interventionNames":["Drug: SPARC0921"]},{"label":"Placebo0921","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo0921"]}],"interventions":[{"name":"SPARC0921","otherNames":[]},{"name":"Placebo0921","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women age 18 years and older\n* Able and willing to comply with the protocol, including availability for a scheduled clinic visits\n* Willingness and giving of written informed consent\n\nExclusion Criteria:\n\n* In relapse or history of unstable course over the prior 30 days prior to the Screening Visit\n* Concomitant neurologic conditions causing spasticity\n* Has received an investigational drug or device within 30 days that would interfere with the study goals prior to the Screening Visit\n* Unable to comply with study procedures in the opinion of the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Failure Rate","description":"Percentage of subjects who had treatment failure Clinical Global Impression of Change of ≥ 5 and at least one movement with ≥ 1 unit increase in modified Ashworth score from baseline.\n\nThe modified Ashworth scale is a 6-point scale as follows: Minimum score of 0 (better outcome) = no increase in tone Maximum score of 4 (worst outcome) = affected part(s) rigid inflexion or extension.\n\nThe clinician (other than the one performing the Modified Ashworth Scale assessment) rated his/her overall (global) impression of change in spasticity using the 7-point scale shown below: Minimum score of 1 (better outcome) = very much improved Maximum score of 7 (very much worse) = very much worse","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"43.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Spasticity Assessed by Subject Global Impression Severity Scale","description":"The subject was asked \"Overall, how would you rate the severity of your spasticity over the past 24 hours?\" The 7-point scale for Subject's global impression of severity assessment is as follows: minimum score of 1 = normal, no spasticity maximum score of 7 (worst outcome)= worst spasticity imaginable","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"14.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":147},"commonTop":["Muscle spasticity","Fatigue","Headache","Nausea","Urinary tract infection"]}}}